The pharmaceutical industry has traditionally been a European-centric industry for many years. However, this dominance is rapidly declining due to a combination of U.S. policy changes and the rise of China as a biotech leader.
Europe, which was once considered the center of innovation and development in the world of pharmaceuticals, has now become much less competitive due to deep-rooted issues within the system (i.e. inefficiencies within the system, lack of investment, and fragmented regulation).
Approximately 30 years ago, Europe made up nearly 50% of the worldwide R&D effort within the pharmaceutical industry whereas the United States only accounted for roughly 33%. Today this balance has reversed.
The U.S. now accounts for approximately 55% of global R&D while Europe owns a very small percentage (26%). The reason for this rapid decline is due to a combination of systemic weaknesses such as fragmented regulatory systems across 27 member states, inconsistent pricing and reimbursement processes, and a lack of available venture capital.
Therefore; biotech companies in Europe receive 5-10 times less venture capital as compared to companies in the U.S., which has greatly limited their potential for scaling innovation.
As a result of the introduction of policies under the Trump Administration that increased competitive pressure on U.S. pharmaceutical companies, the U.S. has introduced tariffs of up to 100% on branded pharmaceuticals as well as implemented “most-favored-nation” pricing strategy upon U.S. prices to the lowest offered globally.
These policies have effectively created a price dilemma for pharmaceutical companies with respect to their pricing strategies for their products globally; i.e., does a company choose to launch their product within a lower-priced European market and risk lower sales in the U.S. or vice versaA RAND report estimates that pharmaceutical prices in the U.S. are almost three times as high as those in other high-income countries.
Pharmaceutical product introductions into Europe continue to be delayed as pharmaceutical companies now place greater relative weight on the North American market than on Europe.
China has also become a huge global competitor, and its contribution to the global drug development pipeline is nothing short of astonishing. In 2012, for instance, China contributed only 4% of the molecules in the global drug pipeline; by 2023, it will contribute roughly one-third of all molecules in the global drug pipeline.
China's increase has stemmed from strong governmental support, robust private and public investments in targeted funds, and rapidly evolving innovation ecosystems. In addition to becoming the largest net recipient of foreign R&D investment, leading pharmaceutical companies around the globe are now looking to China for cost savings and innovative R&D partnerships.
The enormous increase in foreign investment in R&D is a clear sign of a bigger shift in the global life sciences market and a transformation in the geopolitical landscape.
In addition to increased competition from China, Europe's internal policy framework has contributed to creating additional barriers to success for European pharmaceutical companies.
The pharmaceutical industry in the European Union invests approximately 1% of its GDP in pharmaceuticals compared to 2% of GDP by the U.S. and 1.8% of GDP from China. Factors like price controls, tax clawbacks, and long waits for approval will continue to negatively affect the ability of pharmaceutical manufacturers to make investments in Europe, thereby enabling many patients in Europe to be delayed in accessing newer therapies.
In fact, many of the largest pharmaceutical manufacturers have already withdrawn or significantly reduced their investments in the U.K. because of this difficult business climate, including AstraZeneca, Eli Lilly, and Merck.
While all of the above issues are exceedingly challenging for European pharmaceutical companies, there is still time for Europe to counteract the downward spiral.
For instance, the present proposals for the Biotech Act and the Critical Medicines Act include provisions to remove regulatory impediments, expedite the duration of clinical trials and enhance the strength of the global supply chain for pharmaceutical products in the E.U. Also, Spain has shown that concentrating on reform can help in increasing the number of clinical trials in the country.
However, the recovery from the decline in pharmaceutical research and development investments by European firms will not have uniform activity and will be slower than the rapidly evolving competitive environment created by China.
Europe's pharmaceutical decline has arisen from a lack of coordination, investment, and prioritization; if there is not a rapid development and implementation of coordinated partnerships among European countries to develop initiatives to ensure that Europe retains its leadership position in global drug innovation, it is possible that its current first-tier international position in drug discovery will no longer be maintained.
ISSUE
Leave a Comment